Doximity (NYSE: DOCS) shares initially jumped as much as 100% on Friday after the company reported fiscal first-quarter results that beat revenue estimates and raised its full-year outlook. However, the rally has since faded, with shares now trading roughly 33% above Thursday's close, as investors take a closer look at the underlying fundamentals.
The digital health platform for medical professionals reported total revenue of $156.6 million, up just 7% year-over-year. While management framed the quarter as a "reacceleration," the single-digit growth is modest for a company trading at premium software multiples. The core advertising business, which relies heavily on pharmaceutical clients, remains constrained by tightening healthcare marketing budgets, suggesting that a true acceleration has yet to materialize in reported sales.
Guidance: More conservative than it appears
The initial surge was largely driven by the company's raised full-year revenue guidance to $671 million to $681 million, an increase of $6 million from the prior range. However, this adjustment merely passes through the first-quarter beat of $4.9 million, leaving the back-half expectations essentially unchanged. Moreover, the company's second-quarter revenue guidance of $170 million to $171 million came in line with consensus estimates of $171.1 million, offering no upside surprise for the current quarter.
This pattern suggests that management is not signaling a meaningful acceleration in the near term, which may explain why the stock is giving back gains. As seen with other tech names like SoundHound's rally masking underlying losses, market enthusiasm can quickly fade when fundamentals don't support the valuation.
AI investments could pressure margins
Much of the post-earnings commentary centered on Doximity's AI Search tool, which has generated excitement among investors. However, the company disclosed that no revenue from its new AI tools was recognized in the first quarter. CFO Matthew Sonefeldt noted that "higher-than-expected" AI usage will require expanding AI infrastructure investments in fiscal 2027, which could weigh on the company's impressive 48% adjusted EBITDA margin as computing costs for clinical large language model queries scale.
This is a familiar theme across the tech sector, where AI-driven growth often comes with significant capital expenditures. For Doximity, the potential margin erosion is a key risk that investors are now pricing in.
Customer retention and EPS miss
Another concerning metric is the net revenue retention rate, which stood at 107% on a trailing 12-month basis. Even among the top 20 largest clients, NRR was 112%, well below the 115% to 120% typically seen at premium SaaS and enterprise health platforms. This indicates that upselling existing pharmaceutical brands and hospital networks remains sluggish.
Additionally, Doximity reported adjusted earnings per share of $0.29, missing the consensus estimate of $0.30. The combination of weak retention, an EPS miss, and rising AI costs paints a picture of a company that may struggle to justify its post-rally valuation.
Investors have seen similar post-earnings reversals in other tech stocks, such as Kioxia's plunge despite strong earnings, where market expectations outpace actual results. Doximity's reversal appears to be a rational response to the data, rather than a market overreaction.
For those considering whether to hold or trim positions, the current pullback may be an opportunity to reassess the risk-reward profile. As the company continues to invest in AI and navigate a challenging advertising environment, the path to sustained growth remains uncertain.
This article is for informational purposes only and does not constitute financial advice.
